Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2023
Reporting Period: Event date November 2, 2023; Report signed November 8, 2023.
The Company entered into a material definitive agreement to advance its reduced nicotine content tobacco development using non-GMO technology.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The only specific financial metric disclosed is the value of equity consideration issued:
- Stock Consideration: Shares of common stock valued at $100,000 issued to North Carolina State University (NCSU).
- Valuation Method: Based on the twenty-day average closing price of the Company's common stock immediately preceding November 2, 2023.
- Debt and Liquidity: The filing text does not provide a clear value for current debt levels or liquidity positions.
Material Changes and Agreements
Item 1.01: Entry Into a Material Definitive Agreement
The Company executed an exclusive licensing agreement with North Carolina State University (NCSU) on November 2, 2023.
- Subject Matter: Exclusive rights to Patent Rights and Plant Materials for developing reduced nicotine content tobacco.
- Term: Country-by-country basis until the expiration of the last patent or plant variety right, or November 2, 2042, if no patents issue.
- Financial Obligations: The Company must pay licensing fees, maintenance fees, milestone payments upon achieving performance goals, sublicensing fees, and ongoing royalty fees.
- Termination: Either party may terminate for material breach (subject to cure periods) or insolvency.
Item 3.02: Unregistered Sales of Equity Securities
The issuance of the $100,000 stock consideration was conducted as a private placement exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Guidance, Outlook, and Risks
Management Commentary: The agreement is intended to allow the Company to develop and commercialize reduced nicotine content tobacco using the latest non-GMO technology. A press release regarding this agreement was issued on November 7, 2023.
Risks and Contingencies:
- Performance Risk: Future payments are contingent on achieving specific performance goals (milestone payments).
- Termination Risk: The agreement is subject to termination in the event of material breach or insolvency.
- Regulatory Risk: The issuance of shares is subject to restrictions, representations, and conditions outlined in the agreement.
Investor Verification Checklist
- Verify the exact number of shares issued to NCSU by calculating the $100,000 value against the twenty-day average closing price prior to November 2, 2023.
- Review the full text of the NCSU License Agreement (Exhibit 10.1) to understand specific milestone definitions and royalty rates.
- Confirm the impact of the $100,000 stock issuance on total outstanding shares and potential dilution.
- Monitor future filings for the achievement of performance milestones triggering additional payments.